Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types
Mené sur 53 patients atteints d'une tumeur solide de stade métastatique ou localement avancé, puis sur 184 patients atteints d'un cancer du poumon non à petites cellules de stade avancé ou métastatique, récidivant ou réfractaire à un traitement à base de sels de platine, cet essai de phase Ia et de phase Ib évalue les caractéristiques pharmacocinétiques, la dose maximale tolérée, l'activité antitumorale, la toxicité et l'efficacité, du point de vue du taux de réponse objective, de l'avélumab, un anticorps monoclonal anti-PD-L1
During the past 5 years, immune checkpoint inhibitors have revolutionised the management and treatment of cancer, because they have been associated with striking improvements in clinical outcomes in patients with some tumour types. For example, the use of checkpoint inhibitors has changed the natural history of melanoma with a pronounced increase in patients' survival.1,2 These agents have also been tested in many other tumour types, such as renal cancer, urothelial cancer, and squamous cell cancer of the head and neck, with promising results and have subsequently gained approval from the regulatory authorities.
The Lancet Oncology , commentaire, 2016